Open AccessOPTIMIZATION OF TREATMENT OF PATIENTS WITH INSULIN RESISTANCE TO REDUCE THE EXPRESSIVENESS OF CARDIOVASCULAR RISK FACTORS
Author(s) -
N. I. Vynnyk,
Анна Володимирівна Лавренко,
Ігор Петрович Кайдашев,
Златослава Олексіївна Шаєнко
Publication year - 2018
Publication title -
lìkarsʹka sprava/lìkarsʹka sprava
Language(s) - English
Resource type - Journals
eISSN - 2706-8803
pISSN - 1019-5297
DOI - 10.31640/jvd.1-2.2018(17
Subject(s) - insulin resistance , pioglitazone , medicine , angina , insulin , cardiology , cholesterol , heart failure , endocrinology , diabetes mellitus , type 2 diabetes , myocardial infarction
In patients with CHD and AH associated with MS the TG level is higher and HDL cholesterol is lower in the group with high insulin resistance (HOMA-index 7.52 ± 0.74), as compared to the group with low insulin resistance (НОМА-index 1,92 ± 0.31). More severe manifestations of CHD, namely, exertional angina pectoris and heart failure, have been found in individuals with high IR. Treatment with 30 mg pioglitazone once daily during 3 months leads to reduction of IR level by 2 times, more significant lowering of TG level and increase of HDL cholesterol in patients with high IR. Thus, it has been confirmed that the leading factors of global cardiovascular risk is closely related to IR. It is proposed to consider the issue regarding the prophylactic use of PG in individuals with high IR to reduce IR.